ARWR·Arrowhead Pharmaceuticals Inc.
ARWR|Analyst Targets
ARWR|Insider Trading
ARWR|Fundamentals
ARWR|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q4'26 | $-1.54 | - | - |
| Q3'25 | $-0.16 | $-0.18 | -14.5% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q4'26 | $54M | - | - |
| Q3'25 | - | $256M | - |
ARWR|Monthly Returns
Market Data
ARWR Stock Snapshot
- Market cap
- 8.57B
- Day range
- $58.77 – $59.24
- News sentiment
- 70/100 · Bullish
- Analyst target
- $107.23 (+82.5%)
- Consensus
- Buy · 22 analysts
Momentum is working in ARWR's favour - it ranks in the upper part of DailyIQ's momentum universe. Position sizing matters more than usual in a name this size, where volatility is structural.
Behaviour On Record
What ARWR's own history says about today's numbers
- Realized volatility (21d)
- 62.4% 52nd pct
- Below its peak
- -30.5%
- vs 200-day average
- -13.2%
- Up days (1y)
- 48%
Arrowhead Pharmaceuticals Inc. is currently running 62.4% annualised volatility over the last 21 sessions. Measured against ARWR's own 13 years of daily returns rather than a market-wide average, that is the 52nd percentile — close to its own typical level, against a typical reading of 61.2%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.
ARWR is trading -30.5% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -51.0%, and the deepest was -84.7% in 2016. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.
Price sits -13.2% from its 200-day moving average. Against every other day in its history, that gap ranks at the 35th percentile — close to the gap it normally carries. Over the past year ARWR closed higher on 48% of sessions, and it is currently 1 session into a rising streak.
On October specifically: over 13 years of records, ARWR finished the month higher 6 of 13 times, with a median return of -6.3% and an average of -4.3%. Its strongest month historically has been December at +10.3% on average, its weakest March at -10.6%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.
Overnight risk is measurable too: ARWR has opened more than 2% away from the prior close in 528 of 3,266 sessions (16.2% of the time), with the largest gaps running +21.1% and -15.5%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.
All figures computed from 3,267 daily closes between 2013-10-14 and 2026-10-09, split-adjusted, recomputed daily. Percentiles are against ARWR's own 13-year history, not a peer group or index.
Sector Rotation
Is money rotating into or out of ARWR's sector?
Arrowhead Pharmaceuticals Inc. sits in the Health Care sector, currently ranked 4th of 12 GICS sectors by relative-strength rotation score (improving). Within its narrower Biotechnology industry group, ARWR ranks 13th of 15 tracked industries, lagging.
- Sector rank
- #4 of 12
- Sector state
- Improving
- Sector rotation score
- 73
- Industry rank
- #13 of 15
Analyst Rating Changes
Are analysts turning bullish or bearish on ARWR?
Citigroup most recently initiated coverage on Arrowhead Pharmaceuticals Inc. to Buy on Sep 8, 2026 with a price target of $108. Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.
- Latest action
- Citigroup — Buy
- 90-day upgrades
- 0
- 90-day downgrades
- 0
- Net rating momentum
- 0
ETF holders
ETFs holding ARWR
News Sentiment Analysis
Sentiment gathered from recent headlines
Recent News Coverage
Most recent articles, ranked by recency (click to expand).
Technical Analysis
Real-time indicators across multiple timeframes
| Manager | Trend | Shares Held | % of Co. | Position Value | Filed |
|---|---|---|---|---|---|
| BlackRock, Inc. | ▼ Sell | 14,830,553 | 10.12% | $1.21B | 2026-08-07 |
| Vanguard Group Inc | ▼ Sell | 15,293,121 | 10.44% | $1.02B | 2026-01-29 |
| FMR LLC (Fidelity) | ▲ Buy | 8,039,804 | 5.49% | $655.32M | 2026-08-13 |
| Norges Bank | ▲ Buy | 3,896,536 | 2.66% | $317.61M | 2026-08-12 |
| Invesco Ltd. | ▲ Buy | 3,883,976 | 2.65% | $316.58M | 2026-08-14 |
| Geode Capital Management, LLC | ▼ Sell | 3,530,612 | 2.41% | $298.81M | 2026-08-12 |
| Northern Trust Corp | ▼ Sell | 1,192,868 | 0.81% | $97.23M | 2026-08-13 |
| Goldman Sachs Group Inc | ▼ Sell | 1,150,007 | 0.78% | $93.74M | 2026-08-14 |
| Bank of America Corp | ▲ Buy | 1,139,810 | 0.78% | $92.91M | 2026-08-14 |
| Janus Henderson Group plc | ▲ Buy | 1,436,990 | 0.98% | $90.12M | 2026-05-18 |
| Morgan Stanley | ▲ Buy | 1,084,835 | 0.74% | $88.43M | 2026-08-13 |
| Fisher Asset Management, LLC | ▼ Sell | 957,691 | 0.65% | $78.06M | 2026-08-04 |
| JPMorgan Chase & Co | ▼ Sell | 637,399 | 0.43% | $51.77M | 2026-08-12 |
| Susquehanna International Group, LLP | ▲ Buy | 596,573 | 0.41% | $48.63M | 2026-08-14 |
| Two Sigma Investments, LP | ▲ Buy | 580,609 | 0.40% | $47.33M | 2026-08-14 |
| Balyasny Asset Management L.P. | ▲ Buy | 470,754 | 0.32% | $38.37M | 2026-08-14 |
| Renaissance Technologies LLC | ▼ Sell | 468,921 | 0.32% | $38.22M | 2026-08-13 |
| D. E. Shaw & Co., Inc. | ▼ Sell | 431,560 | 0.29% | $35.18M | 2026-08-14 |
| Millennium Management LLC | ▲ Buy | 329,337 | 0.22% | $26.84M | 2026-08-14 |
| Artisan Partners Limited Partnership | ▲ New | 310,706 | 0.21% | $25.33M | 2026-08-13 |
| Marshall Wace, LLP | ▲ Buy | 305,031 | 0.21% | $24.86M | 2026-08-13 |
| Citigroup Inc | ▲ Buy | 264,678 | 0.18% | $21.57M | 2026-08-03 |
| Squarepoint Ops LLC | ▲ Buy | 255,907 | 0.17% | $20.86M | 2026-08-14 |
| AQR Capital Management LLC | ▲ Buy | 198,842 | 0.14% | $15.82M | 2026-08-14 |
| AllianceBernstein L.P. | ▼ Sell | 173,265 | 0.12% | $10.86M | 2026-08-14 |